NGM Biopharmaceuticals (NGM) News Today → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free NGM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | finance.yahoo.comSwedish Exchange Highlights Three Growth Companies With High Insider OwnershipApril 5, 2024 | finanznachrichten.deNGM Biopharmaceuticals, Inc.: NGM Bio Announces Closing of Tender OfferApril 5, 2024 | globenewswire.comNGM Bio Announces Closing of Tender OfferApril 5, 2024 | marketbeat.comTrading was temporarily halted for "NGM" at 07:04 PM with a stated reason of "News pending."March 19, 2024 | globenewswire.comNGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual MeetingMarch 13, 2024 | businesswire.comNGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGMMarch 12, 2024 | bizjournals.comHow a VC and a biotech founder plan to create a new biotech modelMarch 12, 2024 | msn.comOracle, Dollar General upgraded: Wall Street's top analyst callsMarch 12, 2024 | marketbeat.comNGM Biopharmaceuticals (NASDAQ:NGM) Lowered to "Market Perform" at Raymond JamesRaymond James cut NGM Biopharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Tuesday.March 11, 2024 | globenewswire.comNGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | marketbeat.comNGM Biopharmaceuticals (NASDAQ:NGM) Downgraded to Neutral at B. RileyB. Riley lowered NGM Biopharmaceuticals from a "buy" rating to a "neutral" rating in a research note on Wednesday.February 29, 2024 | msn.comTD Cowen Downgrades NGM Biopharmaceuticals (NGM)February 28, 2024 | marketbeat.comTD Cowen Downgrades NGM Biopharmaceuticals (NASDAQ:NGM) to Market PerformTD Cowen lowered NGM Biopharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Wednesday.February 27, 2024 | businesswire.comNGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGMFebruary 27, 2024 | marketbeat.comNGM Biopharmaceuticals (NASDAQ:NGM) Downgraded by CitigroupCitigroup cut NGM Biopharmaceuticals from a "buy" rating to a "neutral" rating in a research note on Tuesday.February 26, 2024 | bizjournals.comThe Column Group moves forward with plan to take NGM Bio privateFebruary 26, 2024 | finanznachrichten.deNGM Biopharmaceuticals, Inc.: NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPFebruary 26, 2024 | markets.businessinsider.comNGM Bio To Be Acquired By Affiliates Of The Column Group, LPFebruary 26, 2024 | finance.yahoo.comNGM to go private through deal with investment firmFebruary 26, 2024 | marketwatch.comNGM Biopharmaceuticals Shares Drop 20% After $1.55/Shr Buyout OfferFebruary 26, 2024 | businesswire.comNGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to ShareholdersFebruary 26, 2024 | marketwatch.comNGM Biopharmaceuticals Gets Buyout Offer From Column Group AffliatesFebruary 26, 2024 | msn.comNGM Bio to go private in a $135M deal with Atlas NeonFebruary 26, 2024 | globenewswire.comNGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPFebruary 26, 2024 | marketbeat.comTrading was temporarily halted for "NGM" at 08:02 AM with a stated reason of "News pending."February 25, 2024 | marketbeat.comNGM Biopharmaceuticals (NGM) Scheduled to Post Earnings on MondayNGM Biopharmaceuticals (NASDAQ:NGM) will be releasing earnings on Monday, February 26, Yahoo Finance reports.February 22, 2024 | finance.yahoo.comAscites Market to Observe Stunning Growth During the Study Period (2019–2032) | DelveInsightFebruary 20, 2024 | finance.yahoo.comNGM Bio to Participate in the Cowen 44th Annual Health Care ConferenceFebruary 20, 2024 | globenewswire.comNGM Bio to Participate in the Cowen 44th Annual Health Care ConferenceFebruary 17, 2024 | marketbeat.comNGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Sees Significant Increase in Short InterestNGM Biopharmaceuticals, Inc. (NASDAQ:NGM - Get Free Report) was the target of a significant increase in short interest in January. As of January 31st, there was short interest totalling 1,680,000 shares, an increase of 9.1% from the January 15th total of 1,540,000 shares. Based on an average daily volume of 961,800 shares, the short-interest ratio is currently 1.7 days. Currently, 4.1% of the company's stock are sold short.February 13, 2024 | ca.finance.yahoo.comNGM Biopharmaceuticals, Inc. (NGM)January 19, 2024 | benzinga.comLooking Into NGM Biopharmaceuticals's Recent Short InterestJanuary 17, 2024 | finance.yahoo.comNGM Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceJanuary 14, 2024 | marketbeat.comNGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Short Interest Down 34.4% in DecemberNGM Biopharmaceuticals, Inc. (NASDAQ:NGM - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 1,640,000 shares, a decrease of 34.4% from the December 15th total of 2,500,000 shares. Based on an average daily trading volume, of 993,600 shares, the short-interest ratio is currently 1.7 days. Currently, 4.0% of the shares of the company are short sold.January 9, 2024 | msn.comNGM Biopharma gains on Phase 1 data update for cancer therapyJanuary 9, 2024 | benzinga.comNGM Biopharmaceuticals Stock (NASDAQ:NGM) Dividends: History, Yield and DatesJanuary 9, 2024 | finance.yahoo.comNGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet NeedJanuary 3, 2024 | bizjournals.comBiotech VC wants to take one of its portfolio companies private againJanuary 3, 2024 | finance.yahoo.comGreat week for NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) institutional investors after losing 75% over the previous yearJanuary 2, 2024 | msn.comNGM Biopharma jumps on take-private offerJanuary 2, 2024 | benzinga.comWhy NGM Biopharmaceuticals Stock Is Blasting HigherNovember 24, 2023 | morningstar.comNGM Biopharmaceuticals Inc NGMNovember 22, 2023 | markets.businessinsider.comB. Riley Securities Maintains Buy Rating for NGM Biopharmaceuticals: Here's What You Need To KnowNovember 22, 2023 | finance.yahoo.comHere's Why We're A Bit Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn SituationNovember 20, 2023 | msn.comNGM Biopharmaceuticals 10% owner Column Group discloses purchase of over 22K sharesNovember 17, 2023 | morningstar.comNGM Biopharmaceuticals Inc 0IKNovember 13, 2023 | finance.yahoo.comNGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®November 9, 2023 | benzinga.comChief Executive Officer at NGM Biopharmaceuticals Exercises Options Worth $2.24MNovember 9, 2023 | benzinga.comSVP at NGM Biopharmaceuticals Exercises Options Worth $412KNovember 9, 2023 | benzinga.comNGM Biopharmaceuticals EVP Acquires 615,000 Shares After Exercising Company Stock Options Get NGM Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NGM and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide NGM Media Mentions By Week NGM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NGM News Sentiment▼0.000.42▲Average Medical News Sentiment NGM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NGM Articles This Week▼11▲NGM Articles Average Week Get NGM Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NGM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LIAN News Today KPTI News Today CNTX News Today TBRG News Today SY News Today MOLN News Today OPTN News Today PDSB News Today AMLX News Today OMGA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NGM) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldUrgent Nvidia WarningAltimetryDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyShocking: One AI startup's revenue could surge 4,735%Manward PressThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NGM Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
